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The objective of the DILT1D trial is to identify doses of
interleukin-2 that achieve targeted increases in the T
regulatory cell population in recently diagnosed type 1
diabetes. DILT1D aims to accurately identify a mini-
mally effective dose and a maximal dose in a limited
number of patients (40) that may be repeatedly adminis-
tered in later phase trials.
The dose is administered subcutaneously so can be
chosen from a continuous range up to a limit chosen on
tolerability grounds. The design has an initial learning
phase where pairs of patients are assigned to five pre-
assigned doses. The next phase is fully sequential with
an interim analysis after each patient to determine the
choice of dose based on the optimality criterion to mini-
mise the determinant of the covariance of the estimated
target doses. The dose-choice algorithm assumes that a
specific parametric dose-response model is the true rela-
tionship, and so a variety of models are considered at
the interim and human judgement involved in the over-
all decision.
Simulation studies found that having two targets and
assuming a model with a small number of parameters
(≤3) leads to a choice of doses that are not near to the
target doses. Fitting models with greater flexibility with
more parameters (≥4) results in a choice of doses near
to the target doses. Overall the design is efficient and
seamlessly combines the initial learning and subsequent
confirmatory stages.
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